2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

506. Bone Marrow Microenvironment: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Omics Technologies, Bioinformatics, Cell Expansion, Gene Editing, Profiling, Treatment Considerations, Biological Therapies, Transplantation, Immunotherapy, Biological Processes, Pathogenesis, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Practice Models, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, CML, Study Population, Human, Animal Model
PAPER

1385 Dynamic regulation of HSC and LSC fate in chronic myeloid leukemia through macrophage engagement of CD44

Tiff Ricketts, PhD, Na Xie, PhD2, V K Chaithanya Manam3, Mason Harris4, Changde Cheng, PhD5, Andrew Paterson, PhD6, Ravi Bhatia, MD7
1 University of Alabama at Birmingham Heersink School of Medicine, Birmingham, Alabama, United States
2 University of Alabama at Birmingham Heersink School of Medicine, Birmingham, Alabama, United States
3 University of Alabama at Birmingham Heersink School of Medicine, Birmingham, Alabama, United States
4 University of Alabama at Birmingham Heersink School of Medicine, Birmingham, Alabama, United States
5 University of Alabama at Birmingham Heersink School of Medicine, Birmingham, Alabama, United States
6 University of Alabama at Birmingham Heersink School of Medicine, Birmingham, Alabama, United States
7 University of Alabama at Birmingham Heersink School of Medicine, Birmingham, Alabama, United States

Tyrosine kinase inhibitors (TKIs) are highly effective in managing chronic myeloid leukemia (CML). However, many patients require continued treatment to prevent disease recurrence which has been linked to hematopoietic stem cell (HSC) niche signals that support leukemia stem cells (LSCs) persistence.

Macrophages (MФ) are innate immune phagocytes and residents of the HSC niche that modulate normal and malignant hematopoiesis. We have found that CML bone marrow (BM) MФs acquire an inflammatory phenotype that selectively supports LSC expansion and alters normal HSC function. Conversely, TKI treatment reprograms CML MФs to repair/regulatory phenotypes that enhance normal HSC development. However, specific MФ interactions that differentially regulate HSC/LSC fate in CML are not well characterized. Here, we examine MФ engagement of the HSC and LSC adhesion receptor, CD44, in directing HSC function and response to TKI treatment.

Chimeric CML mice were generated by co-transplantation of BM from an inducible BCR::ABL+ mouse model (CML/BA+) and wildtype (WT) mice, followed by treatment with nilotinib (CMLTKI) or vehicle (CMLVeh) for 28 days. Inference analysis of MФ-HSC interactions using CellChat to probe CITE-seq data revealed a high communication probability between MФ-secreted osteopontin (SPP1) and HSC-expressed CD44 in CMLVeh samples but not control and CMLTKI samples. In contrast, CMLTKI samples showed high probability of MФ-induced TGF-beta (TGFB) signaling in HSCs. Analysis of BM MФs via immunocytochemistry revealed significantly elevated SPP1 in CMLVeh compared to control and CMLTKI BM MФs while TGFB1 was distinctly increased in CMLTKI MФs. Moreover, flow cytometric analysis of hematopoietic stem and progenitor cells (LSK cells) revealed significantly elevated CD44 levels in CML BA+ cells co-cultured with CMLVeh BM MФs compared to WT or BA+ LSK cells cultured without MФs. Likewise, co-culture of CML patient-derived CD34+cells and monocyte-derived MФs (MDMs) revealed increased CD44 expression in the HSC/LSC and MPP pool in comparison to co-culture assays using healthy donor samples.

To assess the functional significance of MФ-derived CD44 signaling on modulating HSC fate in vitro, we employed monoclonal antibody (mAb)-mediated blockade in co-culture assays, followed by analysis of downstream signaling mediators in CML chimeric mice and patient BM samples. Addition of CD44 mAb, clone IM7, had no significant effect on LSCs co-cultured with BM MФs from control and CMLTKI mice, but profoundly reduced LSC expansion in response to CMLVeh MФs. Similarly, CD44 blockade markedly reduced CD34+CD45RA– MPPs and HSCs expressing the LSC-specific marker CD26 in co-culture assays of human CML CD34+ cells and CML MDMs. Exposure to SPP1 alone significantly expanded human CD26+ HSCs, which was also significantly reduced following CD44 blockade. The reduction in BA+ HSCs following CD44 blockade was associated with increased expression of phosphorylated SMAD2/SMAD3, indicating enhanced TGFB activation paired with reduced NFkB p65 activity, which has been linked to the proliferation and survival of LSCs. Conversely, CD44 blockade enhanced expansion of non-leukemic HSCs co-cultured with TKI-treated MФs in both murine and healthy donor samples. This was associated with increased HSC NFkB activation and reduced TKI-treated MФ induction of TGFB-SMAD signaling, which is reportedly involved in the regulation of HSC quiescence and self-renewal. TGFB significantly increased human control but not CML HSCs, which were further increased after CD44 blockade, accompanied by reduced SMAD2/SMAD3 activation.

In summary, we show that MФ-expressed SPP1 and TGFB differentially regulate LSC and HSC growth in CML before and after TKI treatment. SPP1 expressed by inflammatory CML MФs engages CD44 on LSCs to support expansion by enhancing NFkB p65 activation and restricting canonical TGFB signaling. Contrariwise, TGFB expressed by TKI-reprogrammed CML MФs supports non-leukemic HSCs through increased SMAD2/SMAD3 and reduced NFkB signaling. Moreover, CD44 blockade further increases HSC expansion while reducing TGFB-mediated SMAD2/SMAD3 signaling, suggesting that CD44 modulates TGFB activity to control HSC fate. Together, these observations identify CD44 as an important mediator of MΦ–LSC crosstalk and as a promising target for both clearing CML LSCs and promoting non-leukemic HSC recovery, increasing the likelihood of treatment-free remission.
Tiff Ricketts, PhD: No relevant conflicts of interest to declare.